propranolol has been researched along with Ascites in 50 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Ascites: Accumulation or retention of free fluid within the peritoneal cavity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In recent years, concerns have been raised on the potential adverse effects of nonselective beta-blockers, and particularly carvedilol, on renal perfusion and survival in decompensated cirrhosis with ascites." | 9.41 | Conversion of Propranolol to Carvedilol Improves Renal Perfusion and Outcome in Patients With Cirrhosis and Ascites. ( Aggelis, N; Baltayiannis, G; Christaki, M; Christodoulou, D; Despotis, G; Fillipas-Ntekouan, S; Fotopoulos, A; Kalambokis, GN; Koustousi, C; Lakkas, L; Michalis, LK; Milionis, H; Pappas, K; Sergianiti, F; Tsiakas, I; Tsiouris, S; Xourgia, X, 2021) |
| "The effect of spironolactone on esophageal variceal pressure (VP) in patients without ascites was investigated." | 9.08 | The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites. ( Fevery, J; Lijnen, P; Nevens, F; VanBilloen, H, 1996) |
| "It has been suggested that propranolol may have a protective effect on the development of spontaneous bacterial peritonitis by increasing the motility of the bowel and lowering the pressure of the portal vein." | 7.73 | Spontaneous bacterial peritonitis in cirrhotic patients: Is prophylactic propranolol therapy beneficial? ( Archimandritis, AJ; Burroughs, AK; Cholongitas, E; Manesis, EK; Papatheodoridis, GV, 2006) |
| "Propranolol hydrochloride is reported to lower portal pressure and inhibit renin secretion in patients with chronic liver disease, actions that might lessen the tendency to ascites formation." | 7.67 | Propranolol in the treatment of cirrhotic ascites. ( Rector, WG; Reynolds, TB, 1984) |
| "To determine the effect of massive cocaine intoxication on lung water and ascites accumulation and the effect of beta- and alpha-adrenergic blockade on survival in massive cocaine intoxication in the mouse." | 7.67 | Increased lung water and ascites after massive cocaine overdosage in mice and improved survival related to beta-adrenergic blockage. ( Ptashne, KA; Robin, ED; Wong, RJ, 1989) |
| "Propranolol has been used as prophylaxis for variceal bleeding in patients with cirrhosis." | 6.82 | A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis. ( Baik, SK; Jang, JY; Jeong, SW; Kim, DJ; Kim, MY; Kim, SG; Kim, TY; Kim, YS; Lee, B; Seo, YS; Sohn, JH; Suk, KT; Um, SH, 2016) |
| " First-line therapies include carvedilol or propranolol to prevent variceal bleeding, lactulose for hepatic encephalopathy, combination aldosterone antagonists and loop diuretics for ascites, and terlipressin for hepatorenal syndrome." | 5.41 | Diagnosis and Management of Cirrhosis and Its Complications: A Review. ( Parikh, ND; Tapper, EB, 2023) |
| "In recent years, concerns have been raised on the potential adverse effects of nonselective beta-blockers, and particularly carvedilol, on renal perfusion and survival in decompensated cirrhosis with ascites." | 5.41 | Conversion of Propranolol to Carvedilol Improves Renal Perfusion and Outcome in Patients With Cirrhosis and Ascites. ( Aggelis, N; Baltayiannis, G; Christaki, M; Christodoulou, D; Despotis, G; Fillipas-Ntekouan, S; Fotopoulos, A; Kalambokis, GN; Koustousi, C; Lakkas, L; Michalis, LK; Milionis, H; Pappas, K; Sergianiti, F; Tsiakas, I; Tsiouris, S; Xourgia, X, 2021) |
| "100) rebled from esophageal varices within a mean time of 8." | 5.27 | [Propranolol prevention of hemorrhagic recurrence caused by rupture of esophageal varices: worsened prognosis in ascites and jaundice]. ( Attali, P; Buffet, C; Etienne, JP; Ink, O; Pelletier, G; Servent, L, 1985) |
| "The effect of spironolactone on esophageal variceal pressure (VP) in patients without ascites was investigated." | 5.08 | The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites. ( Fevery, J; Lijnen, P; Nevens, F; VanBilloen, H, 1996) |
| "It has been suggested that propranolol may have a protective effect on the development of spontaneous bacterial peritonitis by increasing the motility of the bowel and lowering the pressure of the portal vein." | 3.73 | Spontaneous bacterial peritonitis in cirrhotic patients: Is prophylactic propranolol therapy beneficial? ( Archimandritis, AJ; Burroughs, AK; Cholongitas, E; Manesis, EK; Papatheodoridis, GV, 2006) |
| "Propranolol hydrochloride is reported to lower portal pressure and inhibit renin secretion in patients with chronic liver disease, actions that might lessen the tendency to ascites formation." | 3.67 | Propranolol in the treatment of cirrhotic ascites. ( Rector, WG; Reynolds, TB, 1984) |
| "To determine the effect of massive cocaine intoxication on lung water and ascites accumulation and the effect of beta- and alpha-adrenergic blockade on survival in massive cocaine intoxication in the mouse." | 3.67 | Increased lung water and ascites after massive cocaine overdosage in mice and improved survival related to beta-adrenergic blockage. ( Ptashne, KA; Robin, ED; Wong, RJ, 1989) |
| "Carvedilol is a non-selective beta-blocker (NSBB) acting on hyperdynamic circulation/splanchnic vasodilation and on intrahepatic resistance." | 3.01 | Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension. ( La Mura, V; Reiberger, T; Turco, L; Vitale, G, 2023) |
| "Propranolol has been used as prophylaxis for variceal bleeding in patients with cirrhosis." | 2.82 | A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis. ( Baik, SK; Jang, JY; Jeong, SW; Kim, DJ; Kim, MY; Kim, SG; Kim, TY; Kim, YS; Lee, B; Seo, YS; Sohn, JH; Suk, KT; Um, SH, 2016) |
| "Pregnancy is rare in women with decompensated chronic liver disease." | 2.47 | Successful pregnancy outcome in decompensated chronic liver disease with portal vein thrombosis: case report and review of literature. ( Hussain, R; Kamani, L; Kumar, M; Siddique, S, 2011) |
| "Carvedilol is a potent noncardioselective beta-blocker, with weak vasodilating properties because of alpha 1 blockade." | 2.46 | The role of carvedilol in the management of portal hypertension. ( Hayes, PC; Tripathi, D, 2010) |
| "Ascites, variceal bleeding, hepatic encephalopathy, and hepatorenal syndrome are among the complications you are likely to encounter when caring for a patient with cirrhosis." | 1.42 | Cirrhosis complications: keeping them under control. ( Eliacin, I; Kashan, S; Minor, SE; Whisenant, EB, 2015) |
| "The so-called "low T3 syndrome" has frequently been reported in patients with cirrhosis." | 1.28 | "Low T3 syndrome" in cirrhosis: effect of beta-blockade. ( Bellanova, B; Bernardi, M; De Palma, R; Gasbarrini, G; Pesa, O; Tame, MR; Trevisani, F; Vecchi, F, 1989) |
| "100) rebled from esophageal varices within a mean time of 8." | 1.27 | [Propranolol prevention of hemorrhagic recurrence caused by rupture of esophageal varices: worsened prognosis in ascites and jaundice]. ( Attali, P; Buffet, C; Etienne, JP; Ink, O; Pelletier, G; Servent, L, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (30.00) | 18.7374 |
| 1990's | 3 (6.00) | 18.2507 |
| 2000's | 4 (8.00) | 29.6817 |
| 2010's | 22 (44.00) | 24.3611 |
| 2020's | 6 (12.00) | 2.80 |
| Authors | Studies |
|---|---|
| Singh, V | 1 |
| Kumar, P | 1 |
| Verma, N | 1 |
| Vijayvergiya, R | 1 |
| Singh, A | 1 |
| Bhalla, A | 1 |
| Turco, L | 1 |
| Reiberger, T | 2 |
| Vitale, G | 1 |
| La Mura, V | 1 |
| Tapper, EB | 1 |
| Parikh, ND | 1 |
| Danielsen, KV | 1 |
| Nabilou, P | 1 |
| Wiese, SS | 1 |
| Hove, JD | 1 |
| Bendtsen, F | 4 |
| Møller, S | 4 |
| Yoo, JJ | 1 |
| Kim, SG | 2 |
| Kim, YS | 2 |
| Lee, B | 2 |
| Jeong, SW | 2 |
| Jang, JY | 2 |
| Lee, SH | 1 |
| Kim, HS | 1 |
| Jun, BG | 1 |
| Kim, YD | 1 |
| Cheon, GJ | 1 |
| Kalambokis, GN | 3 |
| Christaki, M | 1 |
| Tsiakas, I | 1 |
| Despotis, G | 1 |
| Fillipas-Ntekouan, S | 1 |
| Fotopoulos, A | 1 |
| Tsiouris, S | 1 |
| Xourgia, X | 1 |
| Lakkas, L | 1 |
| Pappas, K | 1 |
| Michalis, LK | 1 |
| Sergianiti, F | 1 |
| Baltayiannis, G | 3 |
| Christodoulou, D | 3 |
| Koustousi, C | 1 |
| Aggelis, N | 1 |
| Milionis, H | 1 |
| Villanueva, C | 1 |
| Albillos, A | 1 |
| Genescà, J | 1 |
| Garcia-Pagan, JC | 2 |
| Calleja, JL | 1 |
| Aracil, C | 1 |
| Bañares, R | 1 |
| Morillas, RM | 1 |
| Poca, M | 1 |
| Peñas, B | 1 |
| Augustin, S | 1 |
| Abraldes, JG | 2 |
| Alvarado, E | 1 |
| Torres, F | 1 |
| Bosch, J | 2 |
| Hsu, SJ | 1 |
| Huang, HC | 1 |
| Robins, A | 1 |
| Bowden, A | 1 |
| Watson, W | 1 |
| Smith, F | 1 |
| Gelson, W | 1 |
| Griffiths, W | 1 |
| Kimer, N | 1 |
| Feineis, M | 1 |
| Celtik, C | 1 |
| Durmaz, O | 1 |
| Oner, N | 1 |
| Yavuz, T | 1 |
| Gökce, S | 1 |
| Aydogan, A | 1 |
| Nisli, K | 1 |
| Emiroglu, HH | 1 |
| Ömeroglu, RE | 1 |
| Sökücü, S | 1 |
| Minor, SE | 1 |
| Eliacin, I | 1 |
| Kashan, S | 1 |
| Whisenant, EB | 1 |
| Christou, L | 2 |
| Mandorfer, M | 1 |
| Kim, TY | 1 |
| Sohn, JH | 1 |
| Um, SH | 1 |
| Seo, YS | 1 |
| Baik, SK | 1 |
| Kim, MY | 1 |
| Suk, KT | 1 |
| Kim, DJ | 1 |
| Shukla, R | 1 |
| Kramer, J | 1 |
| Cao, Y | 1 |
| Ying, J | 1 |
| Tansel, A | 1 |
| Walder, A | 1 |
| Advani, S | 1 |
| El-Serag, HB | 1 |
| Kanwal, F | 1 |
| Tripathi, D | 1 |
| Hayes, PC | 1 |
| Sersté, T | 2 |
| Melot, C | 2 |
| Francoz, C | 2 |
| Durand, F | 2 |
| Rautou, PE | 2 |
| Valla, D | 2 |
| Moreau, R | 2 |
| Lebrec, D | 3 |
| Thevenot, T | 1 |
| Cervoni, JP | 1 |
| Monnet, E | 1 |
| Sheppard, F | 1 |
| Martino, VD | 1 |
| Krag, A | 2 |
| Kurt, M | 1 |
| Lo, GH | 1 |
| Angeli, P | 1 |
| Agustín, A | 1 |
| Javier, Z | 1 |
| Kumar, M | 1 |
| Kamani, L | 1 |
| Hussain, R | 1 |
| Siddique, S | 1 |
| Burroughs, AK | 2 |
| Tarantino, I | 1 |
| Turnes, J | 1 |
| Rodés, J | 1 |
| Soylu, AR | 1 |
| Dökmeci, G | 1 |
| Tezel, A | 1 |
| Amuca, H | 1 |
| Umit, H | 1 |
| Nidegger, D | 1 |
| Ragot, S | 1 |
| Berthelémy, P | 1 |
| Masliah, C | 1 |
| Pilette, C | 1 |
| Martin, T | 1 |
| Bianchi, A | 1 |
| Paupard, T | 1 |
| Silvain, C | 1 |
| Beauchant, M | 1 |
| Cholongitas, E | 1 |
| Papatheodoridis, GV | 1 |
| Manesis, EK | 1 |
| Archimandritis, AJ | 1 |
| Rector, WG | 1 |
| Reynolds, TB | 1 |
| Eisenburg, J | 1 |
| Nevens, F | 1 |
| Lijnen, P | 1 |
| VanBilloen, H | 1 |
| Fevery, J | 1 |
| Klein, AM | 1 |
| Holzman, IR | 1 |
| Austin, EM | 1 |
| Levy, M | 1 |
| Sabbah, A | 1 |
| Poynard, T | 1 |
| Calès, P | 2 |
| Pasta, L | 1 |
| Ideo, G | 1 |
| Pascal, JP | 1 |
| Pagliaro, L | 1 |
| Bondarenko, IP | 1 |
| Dubinskiĭ, AA | 1 |
| Tereshkin, IG | 1 |
| Bernardi, M | 1 |
| De Palma, R | 1 |
| Trevisani, F | 1 |
| Pesa, O | 1 |
| Tame, MR | 1 |
| Bellanova, B | 1 |
| Vecchi, F | 1 |
| Gasbarrini, G | 1 |
| Robin, ED | 1 |
| Wong, RJ | 1 |
| Ptashne, KA | 1 |
| Kandel, G | 1 |
| Diamant, NE | 1 |
| Braillon, A | 1 |
| Tribout, B | 1 |
| Reix, N | 1 |
| Capron, JP | 1 |
| Scheurlen, M | 1 |
| Egberts, EH | 1 |
| Dölle, W | 1 |
| Ink, O | 1 |
| Servent, L | 1 |
| Attali, P | 1 |
| Pelletier, G | 1 |
| Buffet, C | 1 |
| Etienne, JP | 1 |
| Witty, RT | 1 |
| Davis, JO | 1 |
| Shade, RE | 1 |
| Johnson, JA | 1 |
| Prewitt, RL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| To Study the Effect of Nonselective Beta Blockers in Advanced Stage Liver Disease With Ascites[NCT02649335] | Phase 3 | 190 participants (Actual) | Interventional | 2015-07-01 | Completed | ||
| A Novel Algorithm to Stratify Clinical Decompensation Risk in Patients With Compensated Advanced Chronic Liver Disease (CHESS2108)[NCT05100485] | 1,000 participants (Actual) | Observational | 2022-01-01 | Completed | |||
| Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension[NCT01059396] | Phase 4 | 201 participants (Actual) | Interventional | 2010-01-28 | Completed | ||
| CHESS-SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease: an International Multicenter Study (CHESS2102)[NCT04975477] | 1,000 participants (Anticipated) | Observational | 2021-07-16 | Not yet recruiting | |||
| The Effect of Preoperative Beta Blocker Use on Intraoperative Hemodynamics and Postoperative Renal Function in End-stage Liver Disease Patients Undergoing Liver Transplantation[NCT03633812] | 477 participants (Anticipated) | Observational [Patient Registry] | 2016-10-28 | Recruiting | |||
| Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline: A Placebo Controlled, Blinded Pilot Study[NCT02123576] | 12 participants (Actual) | Interventional | 2014-04-30 | Terminated (stopped due to Poor enrollment of study population) | |||
| Pilot Study to Evaluate the Correlation Between ¹³C Methacetin Breath Test (MBT) and HVPG Measurement as a Tool for Identifying Responders to Portal Hypertension Therapy[NCT01851252] | Phase 1 | 19 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT02123576)
Timeframe: baseline and 14 days
| Intervention | g/dL (Mean) |
|---|---|
| Treatment | 0.48 |
| Placebo | 0.03 |
Defined as creatinine level above baseline value after day 7, dialysis or death (NCT02123576)
Timeframe: up to day 14
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 3 |
| Placebo | 3 |
We define as serum creatinine level decreased by >50% from baseline but not to <1.5 mg/dL, without dialysis or HRS recurrence (NCT02123576)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
| Placebo | 2 |
We define this as a decrease in serum creatinine level to <1.5 mg/dL without dialysis or death (NCT02123576)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
| Placebo | 1 |
This will be the combination of transplant free survival and those patients who received liver transplant (NCT02123576)
Timeframe: up to 1 year
| Intervention | days (Mean) |
|---|---|
| Treatment | 102 |
| Placebo | 59 |
(NCT02123576)
Timeframe: day 30 and 180
| Intervention | days (Mean) |
|---|---|
| Treatment | 80 |
| Placebo | 36 |
9 reviews available for propranolol and Ascites
| Article | Year |
|---|---|
Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension.
Topics: Adrenergic beta-Antagonists; Ascites; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal H | 2023 |
Diagnosis and Management of Cirrhosis and Its Complications: A Review.
Topics: Adult; Ascites; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hepatic Enc | 2023 |
Management of ascites in patients with liver cirrhosis: recent evidence and controversies.
Topics: Ascites; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Lypressin; Midodrine; Portasystemic Shunt, T | 2013 |
Beta-blockers in cirrhosis and refractory ascites: a retrospective cohort study and review of the literature.
Topics: Adrenergic beta-Antagonists; Aged; Ascites; Case-Control Studies; Esophageal and Gastric Varices; Fe | 2015 |
The role of carvedilol in the management of portal hypertension.
Topics: Antihypertensive Agents; Ascites; Benzopyrans; Carbazoles; Carvedilol; Drug Therapy, Combination; Et | 2010 |
Successful pregnancy outcome in decompensated chronic liver disease with portal vein thrombosis: case report and review of literature.
Topics: Adult; Antiviral Agents; Ascites; Blood Transfusion; Esophageal and Gastric Varices; Female; Hepatit | 2011 |
[Typical risks in the treatment of acute and chronic liver diseases].
Topics: Androgens; Ascites; Cholestyramine Resin; Cimetidine; Disseminated Intravascular Coagulation; Diuret | 1982 |
Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter
Topics: Adrenergic beta-Antagonists; Ascites; Esophageal and Gastric Varices; Female; Gastrointestinal Hemor | 1991 |
A clinical view of recent advances in ascites.
Topics: Animals; Ascites; Ascitic Fluid; Bacterial Infections; Blood Volume; Body Water; Extracellular Space | 1986 |
9 trials available for propranolol and Ascites
| Article | Year |
|---|---|
Propranolol vs. band ligation for primary prophylaxis of variceal hemorrhage in cirrhotic patients with ascites: a randomized controlled trial.
Topics: Acute Kidney Injury; Ascites; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; L | 2022 |
Conversion of Propranolol to Carvedilol Improves Renal Perfusion and Outcome in Patients With Cirrhosis and Ascites.
Topics: Ascites; Carvedilol; Humans; Kidney; Liver Cirrhosis; Perfusion; Propranolol | 2021 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis.
Topics: Adult; Antihypertensive Agents; Ascites; Carbazoles; Carvedilol; End Stage Liver Disease; Esophageal | 2016 |
Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study.
Topics: Adrenergic beta-Antagonists; Aged; Ascites; Blood Pressure; Cardiovascular Diseases; Combined Modali | 2011 |
Cirrhosis and bleeding: the need for very early management.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Ascites; Double-Blind Method; Esophageal and Gastric Varic | 2003 |
The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Ascites; Atrial Natriuretic Factor; | 1996 |
Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter
Topics: Adrenergic beta-Antagonists; Ascites; Esophageal and Gastric Varices; Female; Gastrointestinal Hemor | 1991 |
Propranolol prevents first gastrointestinal bleeding in non-ascitic cirrhotic patients. Final report of a multicenter randomized trial. The Italian Multicenter Project for Propranolol in Prevention of Bleeding.
Topics: Adolescent; Adult; Aged; Ascites; Clinical Trials as Topic; Female; Follow-Up Studies; Gastrointesti | 1989 |
33 other studies available for propranolol and Ascites
| Article | Year |
|---|---|
Effect of beta-blockers on multiple haemodynamics in cirrhosis: A cross-over study by MR-imaging and hepatic vein catheterization.
Topics: Adrenergic beta-Antagonists; Ascites; Catheterization; Cross-Over Studies; Hemodynamics; Hepatic Vei | 2023 |
Propranolol plus endoscopic ligation for variceal bleeding in patients with significant ascites: Propensity score matching analysis.
Topics: Adrenergic beta-Antagonists; Ascites; Combined Modality Therapy; Endoscopy; Esophageal and Gastric V | 2020 |
Beta-blockers in cirrhosis patients with refractory ascites.
Topics: Adrenergic beta-Antagonists; Ascites; Contraindications; Female; Humans; Liver Cirrhosis; Male; Prop | 2014 |
Investigation of cardiomyopathy in children with cirrhotic and noncirrhotic portal hypertension.
Topics: Adolescent; Antihypertensive Agents; Ascites; Blood Pressure; Cardiomyopathies; Case-Control Studies | 2015 |
Cirrhosis complications: keeping them under control.
Topics: Antihypertensive Agents; Ascites; Diuretics; Furosemide; Hemorrhage; Hepatic Encephalopathy; Humans; | 2015 |
Red signs and not severity of cirrhosis should determine non-selective β-blocker treatment in Child-Pugh C cirrhosis with small varices: increased risk of hepatorenal syndrome and death beyond 6 months of propranolol use.
Topics: Adrenergic beta-Antagonists; Ascites; Child; Esophageal and Gastric Varices; Hepatorenal Syndrome; H | 2016 |
Propranolol use beyond 6 months increases mortality in patients with Child-Pugh C cirrhosis and ascites.
Topics: Ascites; Child; Fibrosis; Humans; Liver Cirrhosis; Propranolol | 2016 |
Nonselective beta blockers in patients with ascites: implications of a nationwide study.
Topics: Adrenergic beta-Antagonists; Ascites; Humans; Propranolol | 2016 |
Risk and Predictors of Variceal Bleeding in Cirrhosis Patients Receiving Primary Prophylaxis With Non-Selective Beta-Blockers.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Ascites; Cohort Studies; Comorbidity; Dose-Response | 2016 |
Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites.
Topics: Adrenergic beta-Antagonists; Aged; Ascites; Contraindications; Female; Follow-Up Studies; Humans; Hy | 2010 |
Is this really the end of beta-blockers in patients with cirrhosis and refractory ascites?
Topics: Adrenergic beta-Antagonists; Ascites; Contraindications; Humans; Hypertension, Portal; Liver Cirrhos | 2011 |
Does cardiac dysfunction explain deleterious effects of beta-blockers in cirrhosis and refractory ascites?
Topics: Adrenergic beta-Antagonists; Ascites; Cardiac Output; Heart Diseases; Humans; Liver Cirrhosis; Propr | 2011 |
Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites.
Topics: Adrenergic beta-Antagonists; Ascites; Humans; Liver Cirrhosis; Propranolol; Treatment Outcome | 2011 |
Effects of beta-blockers on survival for patients with cirrhosis and refractory ascites.
Topics: Adrenergic beta-Antagonists; Ascites; Contraindications; Esophageal and Gastric Varices; Gastrointes | 2011 |
β-blockers and refractory ascites in cirrhosis: the message of a team of true scientists.
Topics: Adrenergic beta-Antagonists; Ascites; Bacterial Infections; Cardiovascular Diseases; Female; Hepator | 2011 |
Beta-blockers in patients with cirrhosis and refractory ascites.
Topics: Adrenergic beta-Antagonists; Ascites; Contraindications; Humans; Liver Cirrhosis; Propranolol | 2011 |
Betablockers induce cardiac chronotropic incompetence.
Topics: Adrenergic beta-Antagonists; Ascites; Cardiovascular Diseases; Female; Humans; Liver Cirrhosis; Male | 2012 |
Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis.
Topics: Antihypertensive Agents; Ascites; Bacterial Infections; Cohort Studies; Drug Therapy, Combination; F | 2003 |
Propranolol does not affect incidence of spontaneous bacterial peritonitis in cirrhotic patients with ascites.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Ascites; Bacterial Translocation; Esophageal and Gastric V | 2003 |
Spontaneous bacterial peritonitis in cirrhotic patients: Is prophylactic propranolol therapy beneficial?
Topics: Adrenergic beta-Antagonists; Aged; Ascites; Ascitic Fluid; Bacterial Infections; Chi-Square Distribu | 2006 |
Propranolol in the treatment of cirrhotic ascites.
Topics: Ascites; Furosemide; Humans; Liver Cirrhosis; Natriuresis; Propranolol; Triamterene | 1984 |
Fetal tachycardia prior to the development of hydrops--attempted pharmacologic cardioversion: case report.
Topics: Ascites; Digoxin; Edrophonium; Female; Fetal Diseases; Humans; Infant, Newborn; Male; Maternal-Fetal | 1979 |
Sodium retention in dogs with cirrhosis and ascites: efferent mechanisms.
Topics: Aldosterone; Animals; Ascites; Blood Pressure; Cardiac Output; Denervation; Dogs; Estrogens; Female; | 1977 |
[Letter: action of beta-blocking agents in decompensated cirrhosis].
Topics: Ascites; Drug Evaluation; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Propranolol; Water-Ele | 1976 |
Propranolol in the prevention of ascites.
Topics: Ascites; Follow-Up Studies; Humans; Liver Diseases; Propranolol | 1991 |
[The use of anaprilin for the correction of portal hypertension in liver cirrhosis].
Topics: Adult; Aged; Ascites; Drug Evaluation; Female; Gastrointestinal Hemorrhage; Hemodynamics; Humans; Hy | 1989 |
"Low T3 syndrome" in cirrhosis: effect of beta-blockade.
Topics: Adult; Aged; Ascites; Euthyroid Sick Syndromes; Female; Gastrointestinal Hemorrhage; Humans; Liver C | 1989 |
Increased lung water and ascites after massive cocaine overdosage in mice and improved survival related to beta-adrenergic blockage.
Topics: Animals; Ascites; Cocaine; Extracellular Space; Lung; Male; Mice; Phentolamine; Propranolol; Pulmona | 1989 |
[Are metoclopramide and propranolol contraindicated, like nonsteroidal anti-inflammatory agents, in patients with cirrhosis and ascites?].
Topics: Anti-Inflammatory Agents; Ascites; Diuretics; Drug Therapy, Combination; Humans; Liver Cirrhosis; Me | 1986 |
[Indications for surgery in portal hypertension from the internist's viewpoint].
Topics: Ascites; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; | 1985 |
[Propranolol prevention of hemorrhagic recurrence caused by rupture of esophageal varices: worsened prognosis in ascites and jaundice].
Topics: Ascites; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Humans; Jaundice; Live | 1985 |
Mechanisms regulating renin release in dogs with thoracic caval constriction.
Topics: Angiotensin II; Animals; Ascites; Blood Pressure; Constriction; Creatinine; Disease Models, Animal; | 1972 |
[Therapeutic methods].
Topics: Amidohydrolases; Ascites; Diuretics; Edema; Heart Diseases; Humans; Hypertension; Propranolol; Water | 1966 |